Lithium remains the most thoroughly studied bipolar medication with the strongest long-term outcomes data — but it’s not the only option, and isn’t appropriate for every patient. The modern bipolar treatment landscape includes anticonvulsant mood stabilizers, atypical antipsychotics, and combinations matched to specific patient profiles.
Understanding the options matters because matched treatment produces dramatically better outcomes than generic prescribing. According to American Psychiatric Association guidelines summarized at psychiatry.org, treatment selection should reflect bipolar subtype, episode polarity, prior response, comorbidities, and tolerability priorities.
Lithium — Still Gold Standard for Many
Lithium has 70+ years of evidence and remains the best-supported long-term mood stabilizer:
- Strongest evidence for suicide prevention in bipolar
- Effective for mania and depression prevention
- Strong evidence for bipolar I; useful for bipolar II
- Mortality benefit in long-term studies
Limitations include narrow therapeutic window (requires blood level monitoring), kidney and thyroid effects requiring monitoring, tolerability issues for some patients (tremor, weight gain, polyuria), and interactions with NSAIDs and ACE inhibitors.
Anticonvulsant Mood Stabilizers
Lamotrigine
Particularly strong evidence for bipolar II depression prevention. Generally well-tolerated. The major issue is the required slow titration to avoid Stevens-Johnson syndrome — typically 4-6 weeks to reach therapeutic dose.
Strengths: depression prevention, weight-neutral, generally well-tolerated long-term.
Limitations: slower onset, less effective for acute mania, drug interactions (oral contraceptives, valproate).
Valproate (Depakote)
Effective for acute mania and maintenance. Particularly useful in mixed episodes and rapid cycling. Reaches therapeutic levels quickly.
Limitations: significant teratogenicity (avoided in women of reproductive age unless absolutely necessary), weight gain, hair thinning, hepatotoxicity risk, drug interactions.
Carbamazepine
Older anticonvulsant, still effective for mania. Less commonly first-line due to drug interactions and side effect profile.
Atypical Antipsychotics
Multiple atypicals have FDA approval for bipolar — for acute mania, depression, mixed episodes, or maintenance:
Quetiapine
FDA-approved for bipolar depression, mania, and maintenance. Particularly useful for bipolar II depression. Sedating — can help with sleep and anxiety.
Lurasidone (Latuda)
FDA-approved for bipolar I depression. Favorable metabolic profile compared to older atypicals. Generally well-tolerated.
Cariprazine (Vraylar)
FDA-approved for bipolar depression, mania, and mixed episodes. Newer option with somewhat different mechanism.
Aripiprazole
FDA-approved for bipolar I mania and maintenance. Generally well-tolerated. Available as long-acting injectable.
Risperidone, Olanzapine
Effective but with greater metabolic side effects. Used when other options have failed or for specific clinical situations.
Olanzapine-Fluoxetine Combination (Symbyax)
FDA-approved for bipolar depression specifically.
Combination Strategies
Many bipolar patients require combinations — particularly those with severe illness, rapid cycling, or treatment resistance:
- Lithium + anticonvulsant
- Mood stabilizer + atypical antipsychotic
- Lamotrigine + another mood stabilizer for breakthrough symptoms
- Antidepressant + adequate mood stabilizer (with caution about switching)
Source: American Psychiatric Association bipolar treatment guidelines.
Matching Medication to Patient
- Bipolar I with classic mania: lithium, valproate, atypicals all first-line
- Bipolar II with depression predominant: lamotrigine, quetiapine, lurasidone preferred
- Mixed features: valproate, atypicals; avoid antidepressant monotherapy
- Rapid cycling: avoid antidepressants; lithium, valproate, lamotrigine combinations
- Women of reproductive age: avoid valproate; consider lamotrigine, lithium, certain atypicals
- Substance use comorbidity: valproate may have additional benefit
- Suicide risk: lithium specifically has anti-suicide evidence
Generic prescribing
Bipolar patients sometimes get default treatments without matching to their specific bipolar profile — missing better options.
Profile-matched treatment
Dr. Farkas matches bipolar medications to subtype, episode pattern, comorbidities, and tolerability priorities.
Sustained mood stability
Properly matched bipolar treatment produces substantially better long-term outcomes than generic mood stabilizer use.
Common Questions About Bipolar Medications
Do I have to take lithium?
Not necessarily — many effective alternatives exist. Lithium remains uniquely strong for some indications (suicide prevention, classic bipolar I), but other options are valid for many patients.
Can I take an antidepressant for my bipolar depression?
Sometimes — but only with adequate mood stabilizer foundation. Some specialists avoid antidepressants in bipolar entirely; others use them with careful monitoring.
Will I need medication forever?
For confirmed bipolar disorder, indefinite maintenance is typically appropriate. Recurrence rates without maintenance are very high. See our related articles on bipolar disorder and bipolar II.
How often will I need lab work?
Lithium and valproate require regular monitoring. Atypicals require metabolic monitoring. Lamotrigine requires less frequent monitoring once stable.